



## Featured Stocks in January's Most Attractive/Most Dangerous Model Portfolios

### Recap From December's Picks

Our Most Attractive Stocks (+2.7%) outperformed the S&P 500 (+0.9%) from December 3, 2020 through January 4, 2021 by 1.8%. The best performing large cap stock gained 18% and the best performing small cap stock was up 12%. Overall, 24 out of the 40 Most Attractive stocks outperformed the S&P 500.

Our Most Dangerous Stocks (+3.6%) underperformed the S&P 500 (+0.9%) as a short portfolio from December 3, 2020 through January 4, 2021 by 2.7%. The best performing large cap stock fell by 5.4% and the best performing small cap stock fell by 11.4%. Overall, 8 out of the 25 Most Dangerous stocks outperformed the S&P 500 as shorts.

The Most Attractive/Most Dangerous Model Portfolios underperformed as an equal-weighted long/short portfolio by 0.5%.

[Learn more about the best fundamental research](#)

The best fundamental data in the world, proven in [The Journal of Financial Economics](#), drives our research. Our proprietary [Robo-Analyst technology](#)<sup>1</sup> scales our forensic accounting expertise ([featured in Barron's](#)) across thousands of stocks<sup>2</sup> to produce an unrivaled database of fundamental data.

Nine new stocks make our Most Attractive list this month, and five new stocks fall onto the Most Dangerous list this month. December's Most Attractive and Most Dangerous stocks were made available to members on January 6, 2021.

Our Most Attractive stocks have high and rising returns on invested capital ([ROIC](#)) and low [price to economic book value ratios](#). Most Dangerous stocks have [misleading earnings](#) and long [growth appreciation periods](#) implied by their market valuations.

### Most Attractive Stocks Feature for January: Allstate Corp (ALL: \$109/share)

Allstate Corp is the featured stock from January's [Most Attractive Stocks Model Portfolio](#). Allstate was also a Long Idea in [May 2020](#) and continues to provide quality risk/reward.

Allstate has grown revenue by 5% compounded annually and net operating profit after-tax ([NOPAT](#)) by 7% compounded annually over the past five years.


The firm's NOPAT margin increased from 6% in 2015 to 13% TTM while its [invested capital turns](#) improved slightly from 1.5 to 1.7 over the same period. The combination of rising margins and invested capital turns drive Allstate's ROIC from 9% in 2015 to 22% TTM. Allstate's profitability helps the firm generate significant free cash flow ([FCF](#)). Since 2015, the firm generated \$12.1 billion (27% of market cap) in cumulative FCF. Over the TTM, Allstate generated \$4.5 billion in FCF.

<sup>1</sup> Harvard Business School features our research automation technology in the case [Disrupting Fundamental Analysis with Robo-Analysts](#).

<sup>2</sup> See how our models and financial ratios are superior to Bloomberg and Capital IQ's (SPGI) analytics in the [detailed appendix of this paper](#).



**Figure 1: Revenue & NOPAT Since 2015**



Sources: New Constructs, LLC and company filings

**ALL Is Undervalued**

At its current price of \$109/share, ALL has a price-to-economic book value ([PEBV](#)) ratio of 0.3. This ratio means the market expects Allstate’s NOPAT to permanently decline by 70%. This expectation seems overly pessimistic for a firm that has grown NOPAT by 7% compounded annually over the past five years.

Even if Allstate’s NOPAT margin falls to 8% (compared to 13% TTM) and the firm grows NOPAT by just 2% compounded annually for the next decade, the stock is worth \$265/share today – a 143% upside. [See the math behind this reverse DCF scenario.](#)

**Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)**

Fact: we provide [superior fundamental data](#) and earnings models – unrivaled in the world.

Proof: [Core Earnings: New Data & Evidence](#), forthcoming in The Journal of Financial Economics.

Below are specifics on the adjustments we make based on Robo-Analyst findings in Allstate’s 10-K and 10-Q’s:

Income Statement: we made \$2.4 billion of adjustments, with a net effect of removing \$688 million in [non-operating income](#) (2% of revenue). You can see all the adjustments made to Allstate’s income statement [here](#).

Balance Sheet: we made \$5.2 billion of adjustments to calculate invested capital with a net decrease of \$530 million. One of the largest adjustments was \$2.6 billion in [other comprehensive income](#). This adjustment represented 10% of reported net assets. You can see all the adjustments made to Allstate’s balance sheet [here](#).

Valuation: we made \$5.2 billion of adjustments with a net impact of decreasing shareholder value by \$5.2 billion. There were no adjustments that increased shareholder value. The most notable adjustment to shareholder value was \$2 billion in [preferred stock](#). This adjustment represents 6% of Allstate’s market cap. See all adjustments to Allstate’s valuation [here](#).




### Most Dangerous Stocks Feature: Avient Corp (AVNT: \$44/share)

Avient Corp (AVNT) is the featured stock from January's [Most Dangerous Stocks Model Portfolio](#).

While Aviant's GAAP net income improved from \$145 million in 2015 to \$523 million TTM, the firm's [economic earnings](#), the true cash flows of the business, fell from \$38 million to -\$93 million over the same time, per Figure 2. More recently, the firm's NOPAT margin fell from 6% in 2019 to 4% TTM and ROIC fell from 6% to 3% over the same time.

**Figure 2: GAAP Net Income vs. Economic Earnings Since 2015**



Sources: New Constructs, LLC and company filings

### AVNT Provides Poor Risk/Reward

Despite its poor fundamentals, AVNT is still priced for significant profit growth and is overvalued.

To justify its current price of \$44/share, Avient must immediately achieve a 8% NOPAT margin (vs. all-time high of 7.2%) and grow NOPAT by 8% compounded annually for the next decade. [See the math behind this reverse DCF scenario](#). This expectation seems overly optimistic given the firm's NOPAT has fallen by 3% compounded annually over the past five years.

Even if Avient can improve its NOPAT margin to 6% (vs. 4% TTM) and grow NOPAT by 7% compounded annually for the next 10 years, the stock is worth just \$34/share today, a 23% downside to the current stock price. [See the math behind this reverse DCF scenario](#).

Each of these scenarios also assumes Avient is able to grow revenue, NOPAT, and FCF without increasing working capital or fixed assets. This assumption is unlikely but allows us to create best-case scenarios that demonstrate how high expectations embedded in the current valuation are. For reference, AVNT's [invested capital](#) has grown by an average of \$107 million (4% of 2019 revenue) over the past 10 years.

### Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)

Fact: we provide [superior fundamental data](#) and earnings models – unrivaled in the world.

Proof: [Core Earnings: New Data & Evidence](#), forthcoming in The Journal of Financial Economics.

Below are specifics on the adjustments we make based on Robo-Analyst findings in Avient's 10-K and 10-Q's:

Income Statement: we made \$664 million of adjustments, with a net effect of removing \$408 million in [non-operating income](#) (16% of revenue). You can see all the adjustments made to Avient's income statement [here](#).

Balance Sheet: we made \$1.7 billion of adjustments to calculate invested capital with a net increase of \$176 million. One of the largest adjustments was \$573 million in [asset write-downs](#). This adjustment represented 22% of reported net assets. You can see all the adjustments made to Avient's balance sheet [here](#).



Valuation: we made \$2.5 billion of adjustments with a net effect of decreasing shareholder value by \$1.6 billion. Apart from total debt, the most notable adjustment to shareholder value was \$34 million in [outstanding ESOs](#). This adjustment represents 1% of Avient's market cap. See all adjustments to Avient's valuation [here](#).

*This article originally published [January 15, 2021](#).*

*Disclosure: David Trainer, Kyle Guske II, Alex Sword, and Matt Shuler receive no compensation to write about any specific stock, style, or theme.*

*Follow us on [Twitter](#), [Facebook](#), [LinkedIn](#), and [StockTwits](#) for real-time alerts on all our research.*



## ***Footnotes adjustments matter. We are the ONLY source.***

---

We provide ratings, models, reports & screeners on U.S. 3,000 stocks, 700 ETFs and 7,000 mutual funds.

**[HBS & MIT Sloan research](#)** reveals that:

- **Markets are inefficiently assessing earnings because no one reads the footnotes.**
- **Corporate managers hide gains/losses in footnotes to manage earnings.**
- **Our technology brings the material footnotes data to market for the first time ever.**

Combining human expertise with NLP/ML/AI technologies ([featured by Harvard Business School](#)), we shine a light in the dark corners (e.g. footnotes) of hundreds of thousands of financial filings to unearth critical details.

The HBS & MIT Sloan paper, [Core Earnings: New Data and Evidence](#), shows how our superior data drives uniquely comprehensive and independent debt and equity research.

This [paper](#) compares our analytics on a mega cap company to other major providers. The Appendix details exactly how we stack up.

**Learn [more](#).**

Quotes from HBS & MIT Sloan professors on our research:

### **Get better research:**

*“...the NC dataset provides a novel opportunity to study the properties of non-operating items disclosed in 10-Ks, and to examine the extent to which the market impounds their implications.” – page 20*

### **Pick better stocks:**

*“Trading strategies that exploit cross-sectional differences in firms’ transitory earnings produce abnormal returns of 7-to-10% per year.” – Abstract*

### **Avoid losses from using other firms’ data:**

*“...many of the income-statement-relevant quantitative disclosures collected by NC do not appear to be easily identifiable in Compustat...” – page 14*

### **Build better models:**

*“Core Earnings [calculated using New Constructs’ novel dataset] provides predictive power for various measures of one-year-ahead performance...that is incremental to their current-period counterparts.” – page 4*

### **Exploit market inefficiencies:**

*“These results ... suggest that the adjustments made by analysts and Compustat to better capture core earnings are incomplete. Moreover, the non-core items identified by NC produce a measure of core earnings that is incremental to alternative measures of operating performance in predicting an array of future income measures.” – page 26*

### **Fulfill fiduciary duties:**

*“An appropriate measure of accounting performance for purposes of forecasting future performance requires detailed analysis of all quantitative performance disclosures detailed in the annual report, including those reported only in the footnotes and in the MD&A.” – page 33-34*



## **DISCLOSURES**

---

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

## **DISCLAIMERS**

---

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.